

HIV Testing and ART Coverage Before a UTT Intervention:

Findings in HPTN 071(PopART)

H Ayles^{1,2}, S Floyd¹, N Mandla³, A Young⁴, D Donnell⁴, N Kasese², A Moore⁵, N Beyers³, S Fidler⁶, R Hayes¹

¹ London School of Hygiene & Tropical Medicine, United Kingdom; ² ZAMBART, University of Zambia, Lusaka, Zambia; ³ Desmond Tutu TB Centre, University of Stellenbosch, South Africa; ⁴ SCHARP, Seattle WA, United States; ⁵ FHI360, Durham NC, United States; ⁶ Imperial College, London, United Kingdom




BACKGROUND

- In 2014 UNAIDS set aspirational "90-90-90" global targets for knowledge of HIV status and ART coverage among people living with HIV
- HPTN071 (PopART) is a 3-arm community randomised trial in 21 communities in Zambia and the Western Cape of South Africa (SA), which tests the impact on HIV incidence of a combination HIV prevention approach (Arms A and B) compared with standard-of-care (Arm C)
- Household-based interventions are provided in Arms A and B, and include a universal offer of HIV testing and support for linkage to HIV care • In Arm A, universal ART is offered to all HIV-positive (HIV+) adults at the clinic, i.e. it is offered irrespective of CD4 count, while in Arm B HIV+
- ART is delivered through routine health care services

individuals are eligible for ART according to national guidelines

• We analyzed baseline data on community-wide uptake of HIV testing and ART, to quantify the level of service expansion required to reach the 90-90-90 targets






Map showing location of communities, and photograph of research assistants who conduct interviews

METHODS

MATCHING OF 21 COMMUNITIES INTO 7 TRIPLETS

- Community = the catchment population of a local health clinic, average adult (age ≥18 years) population size approximately 25,000
- Within each country, communities were grouped into triplets
- 4 triplets in Zambia, and 3 triplets in SA
- Matching based on same geographical area, and similar HIV prevalence according to data available prior to the trial
- Within a triplet, 1 community randomized to Arm A, 1 to Arm B, 1 to Arm C



ENROLMENT OF RESEARCH COHORT

- A randomly-selected cohort (PC) of adults aged 18-44 years was recruited from November 2013 to March 2015 to measure primary and secondary trial outcomes. The target was to enroll 2000 – 2500 adults in each community. Consenting participants provided a blood sample for laboratory HIV testing, and the research questionnaire included questions on previous HIV testing, knowledge of HIV status, and uptake of ART
- In trial arms A and B, analysis was restricted to adults who were enrolled before their household had been visited by the community HIV care providers who deliver the household-based interventions, so as to measure pre-intervention uptake of HIV testing and ART

RESULTS

COHORT ENROLMENT, AND ANALYSIS POPULATION

- 38,691 adults were enrolled in the PC, ~2000 in each trial community
- A total of 5,496 in Arm A and 5,500 in Arm B were enrolled before they were offered the household-based interventions, and 12,287 were enrolled in Arm C, a total of 23,283, among whom age was recorded for 23,279
- By early 2016, 21,894 / 23,279 had a confirmed laboratory HIV test result
- 21,847 / 21,894 answered questions on prior HIV testing (Table 1) Table 1 Analysis nonulation overall and by country (N=21.847)

	Zambia	SA	Overall
Gender			
Men	2,790 (30%)	3,716 (31%)	6,686 (31%)
Women	7,037 (70%)	8,124 (69%)	15,161 (69%)
Age (years)			
18-24	4,517 (45%)	4,008 (34%)	8,525 (39%)
25-29	2,046 (20%)	2,636 (22%)	4,682 (21%)
30-34	1,570 (16%)	2,164 (18%)	3,734 (17%)
35-39	1,122 (11%)	1,653 (14%)	2,775 (13%)
40-44	752 (8%)	1,379 (12%)	2,131 (10%)

HIV PREVALENCE, AND PREVIOUS HIV TESTING

Table 2. HIV prevalence based on laboratory HIV test results, and self-reported information on previous HIV testing, among all adults - by country / gender

	Zambia	SA	Overall
HIV prevalence			
Men	12.6% (374 / 2,970) 7-20% ¹	11.9% (442 / 3,716) 2-23% ¹	12.2% (816 / 6,686) 2-23% ¹
Women	25.1% (1,769 / 7,037) 21-35% ¹	28.7% (2,331 / 8,124) 3-40% ¹	27.0% (4,100 / 15,161) 3-40% ¹
Previously tested for HIV			
Men	69.5% (2,064 / 2,970) 57-84% ¹	69.0% (2,564 / 3,716) 40-81% ¹	69.2% (4,628 / 6,686) 40-84% ¹
Women	87.7% (6,170 / 7,037) 79-99% ¹	88.2% (7,162 / 8,124) 59-96% ¹	87.9% (13,332 / 15,161) 59-99% ¹

¹ Range across communities

• HIV prevalence was 12% in men (816 / 6,686) and 27% (4,100 / 15,161) in women

RESULTS AND CONCLUSION

KNOWLEDGE OF HIV+ STATUS AMONG HIV+ ADULTS

- Among 4,916 adults who were HIV+ based on a confirmed laboratory HIV test result, information on self-reported knowledge of HIV status was available for 4,808 (for 108 adults, data were missing)
- In Zambia, among HIV+ men 47% reported they were HIV+; among HIV+ women 56% reported being HIV+ (Table 3 and Figure 1)
- In SA, among HIV+ men 27% reported they were HIV+; among HIV+ women 50% reported being HIV+

ART UPTAKE AMONG HIV+ ADULTS

- In Zambia, among HIV+ men 32% reported they were on ART; among HIV+ women 37% reported they were on ART
- In SA, among HIV+ men 18% reported they were on ART; among HIV+ women 33% reported they were on ART
- Knowledge of HIV status and ART uptake varied widely among communities

Table 3. Self-reported knowledge of HIV+ status and ART uptake among HIV+ adults - by country / gender

	Zambia	SA	Overall
Knowledge of HIV+ status			
Men	47%	27%	36%
	(173 / 367)	(116 / 427)	(289 / 794)
	28-68% ¹	14-34% ¹	14-68% ¹
Women	56%	50%	52%
	(978 / 1,757)	(1,126 / 2,257)	(2,104 / 4,014)
	40-71% ¹	21-76% ¹	21-76% ¹
ART uptake			
Men	32%	18%	25%
	(117 / 367)	(78 / 427)	(195 / 794)
	12-67% ¹	0-27% ¹	0-67% ¹
Women	37%	33%	34%
	(643 / 1,757)	(738 / 2,257)	(1,381 / 4,014)
	24-62% ¹	12-56% ¹	12-62% ¹

¹ Range across communities


KNOWLEDGE OF HIV+ STATUS. BY AGE GROUP

Table 4. Self-reported knowledge of HIV+ status among HIV+ adults - by age group

				- 7 - 3 - 3 - 1
Age (years)	Men, Zambia	Men, SA	Women, Zambia	Women, SA
18-24	21%	7%	34%	30%
25-29	37%	18%	47%	45%
30-34	43%	27%	62%	54%
35-39	65%	29%	70%	58%
40-44	54%	42%	73%	64%
Overall	47%	27%	56%	50%

• Knowledge of HIV+ status among HIV+ adults increased with age (Table 4)

Figure 1. Self-reported knowledge of HIV+ status and ART uptake, among HIV+ adults



CONCLUSION

- Among HIV+ men, overall around one-third knew their HIV+ status and one-quarter were on ART, across the trial communities, but with considerably higher coverage in Zambia than SA
- Among HIV+ women around half knew their HIV+ status and one-third were on ART, with similar coverage in Zambia and SA
- It is possible that these figures under-estimate knowledge of HIV+ status, and uptake of ART, because some HIV+ men and women may know they are HIV+ but do not wish to disclose this to research interviewers
- These levels are far below 90-90-90 targets, showing that interventions which are effective in delivering universal testing and treatment (UTT) have the potential to have a large impact on knowledge of HIV status and ART uptake at population level
- The HPTN071 (PopART) trial will determine whether, with household and clinic interventions which aim to achieve UTT, the 90-90-90 targets can be reached

ACKNOWLEDGMENTS

HPTN 071 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-AI068619, UM1-Al068617, and UM1-Al068613, with funding from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Additional funding is provided by the International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation, as well as by NIAID, the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH), all part of the U.S. National Institutes of Health (NIH).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, NIMH, NIDA, PEPFAR, 3ie, or the Bill & Melinda Gates Foundation.

For more information, visit **hptn.org** and follow us: Facebook: HIVptn | Twitter: @HIVptn | Youtube: HIVptn







The HIV Prevention Trials Network is sponsored by the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, and the National Institute on Drug Abuse, all components of the U.S. National Institutes of Health.

Presented at the 2016 CROI Conference Boston, MA, USA, February 22-25, 2016